Filing Flows › Elite Pharmaceuticals (ELTP) › Q3 FY26
Elite Pharmaceuticals (ELTP) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Feb 17, 2026
Elite Pharmaceuticals (ELTP) reported revenue of $31.6M for the third quarter fiscal 2026 (Q3 FY26), +120% from a year earlier and -13% from the quarter before. Operating margin was 28.5%, net earnings $18.6M (58.9% of revenue).
Elite Pharmaceuticals, Q3 FY26: revenue $31.6M (+120% year over year), operating margin 28.5%, net earnings $18.6M, operating cash flow −$5.3M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $31.6M | -13% | +120% |
| Gross profit | $13.0M | -8% | +112% |
| Operating profit | $9.0M | +10% | +721% |
| Net earnings | $18.6M | +36% | — |
| Operating cash flow | −$5.3M | -203% | — |
What changed
Revenue was $31.6M in Q3 FY26, up 120% year over year and down 13% from the previous quarter. Manufacturing was the largest line at 99% of revenue. Manufacturing added $17.6M year over year (up 128%), 102% of the total change. Licensing declined 67%.
Gross margin was 41.0%, down 1.6 points from Q3 FY25. Operating profit was $9.0M, a 28.5% margin (up 20.9 points year over year). Of the extra revenue versus Q3 FY25, 46% reached operating profit, above the 8% margin then. Operating expenses fell 22% while revenue rose 120%. Net earnings were $18.6M. The effective tax rate was 10.8%. Non-operating items added $11.8M, 57% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$5.3M. Non-cash charges added back $269K of depreciation and amortization and $45K of share-based compensation. Working capital and other items used $24.2M. Capital expenditures of $206K exceeded it, leaving free cash flow of −$5.5M.
Questions
What was Elite Pharmaceuticals' revenue in the third quarter fiscal 2026?
Elite Pharmaceuticals (ELTP) reported revenue of $31.6M for the third quarter fiscal 2026 (Q3 FY26), +120% from a year earlier and -13% from the quarter before.
Was Elite Pharmaceuticals profitable in the third quarter fiscal 2026?
Operating profit was $9.0M (28.5% of revenue) and net earnings $18.6M.